Albendazole in malignant ascites: a case report and literature review on the successes and adverse effects of therapy


  • Jasmine J. Mui Department of General Surgery, St George Hospital, Gray Street, Kogarah NSW
  • David Morris Peritonectomy Unit, St George Hospital, Gray Street, Kogarah NSW



Albendazole, Malignant ascites, VEGF, Neutropenia


Malignant ascites places a significant burden on the healthcare system and has a profound effect on patient quality of life. Albendazole (ABZ) is an anti-helminthic agent that has shown to rapidly reduce malignant ascites with minimal side effects in pre-clinical trials. The following case study explores the effect of ABZ on ascitic volume in a patient with malignant ascites secondary to metastatic colorectal adenocarcinoma. The patient is a 54-year-old man who underwent an ultrasound guided ascitic drainage for worsening ascites secondary to hepatic metastases from sigmoid adenocarcinoma. He was commenced on ABZ based on literature demonstrating that ABZ decreases the volume of malignant ascites via the inhibition of vascular endothelial growth factor. Over the next week, the volume of ascitic fluid decreased significantly, however the patient developed neutropenia unresponsive to granulocyte colony stimulating factor likely in the context of impaired liver function. The efficacy of ABZ in this case study as well as in the literature demonstrates the promising potential for use in reducing malignant ascites. However, this case demonstrates the need for caution for use in patients with liver impairment due to changes to first pass metabolism leading to increased circulating drug toxicity and thus, adverse outcomes.  


Harding V, Fenu E, Medani H, Shaboodien R, Ngan S, Li HK, et al. Safety, cost-effectiveness and feasibility of daycase paracentesis in the management of malignant ascites with a focus on ovarian cancer. Br J Cancer. 2012;107(6):925-30.

Saâda E, Follana P, Peyrade F, Mari V, François E. Pathogenesis and management of refractory malignant ascites. Bull Cancer. 2011;98(6):679-87.

Pourgholami MH, Cai ZY, Wang L, Badar S, Links M, Morris DL. Inhibition of Cell Proliferation, Vascular Endothelial Growth Factor and Tumor Growth by Albendazole. Cancer Investigation. 2009;27(2):171-7.

Tamsma JT. The Pathogenesis of Malignant Ascites. In: Ceelen WP, editor. Peritoneal Carcinomatosis: A Multidisciplinary Approach. Boston, MA: Springer US; 2007. p. 109-18.

Pourgholami HM, Cai YZ, Lu Y, Wang L, Morris LD. Albendazole: a Potent Inhibitor of Vascular Endothelial Growth Factor and Malignant Ascites Formation in OVCAR-3 Tumor-Bearing Nude Mice. Clinical Cancer Research. 2006;12(6):1928-35.

Castro LSEPW, Kviecinski MR, Ourique F, Parisotto EB, Grinevicius VMAS, Correia JFG, et al. Albendazole as a promising molecule for tumor control. Redox Biology. 2016;10:90-9.

Pourgholami MH, Woon L, Almajd R, Akhter J, Bowery P, Morris DL. In vitro and in vivo suppression of growth of hepatocellular carcinoma cells by albendazole. Cancer Letters. 2001;165(1):43-9.

Pourgholami MH, Szwajcer M, Chin M, Liauw W, Seef J, Galettis P, et al. Phase I clinical trial to determine maximum tolerated dose of oral albendazole in patients with advanced cancer. Cancer Chemotherapy and Pharmacology. 2009;65(3):597.

Morris DL, Jourdan JL, Pourgholami MH. Pilot Study of Albendazole in Patients with Advanced Malignancy: Effect on Serum Tumor Markers/High Incidence of Neutropenia. Oncology. 2001;61(1):42-6.

Arif SH, Shams ul B, Wani NA, Zargar SA, Wani MA, Tabassum R, et al. Albendazole as an adjuvant to the standard surgical management of hydatid cyst liver. International Journal of Surgery. 2008;6(6):448-51.






Case Reports